RAS has been shown to increase radiation resistance. Upstream and downstream pathways from RAS could thus be targets for manipulation of radiosensitivity. EGFR expression and AKT phosphorylation are also associated with the response to radiation. A retrospective study evaluating EGFR and AKT in patients treated with multimodality therapy found a significant association between P-AKT and treatment failure. Moreover, these data are strengthened by in vitro studies showing that inhibition of EGFR, RAS, PI3K, and AKT radiosensitized cancer cell lines. We have previously shown that PI3K is a mediator of RAS-induced radiation resistance. We now suggest that EGFR, which is upstream of PI3K, may also mediate resistance through a common pathway. In addition to EGFR and RAS, PTEN can also regulate the PI3K pathway. Identifying a common signal for EGFR, RAS, or PTEN that results in radiation resistance may uncover targets for developing molecular-based radiosensitization protocols for tumors resistant to radiation and thus improve local control.
Introduction
The sensitivity of cells to killing by ionizing radiation is a critical, although not the sole, determinant of the probability of cure in patients receiving radiotherapy for cancer as shown both in retrospective studies of cancer cell lines (Girinsky et al., 1992) in vitro and in prospective clinical trials (West et al., 1991 (West et al., , 1993 (West et al., , 1995 . One factor known to increase tumor cell survival after radiation is the presence of activated oncogenes. Hence, there has been considerable interest in determining which genes mediate altered radiosensitivity in tumor cells. The ability of the RAS oncogene to lead to increased survival has been indicated through several independent lines of experimentation. First, overexpression or transformation of rodent or human cells by RAS has been shown in many cases to result in cell lines that are substantially more resistant to radiation than the parental cells (FitzGerald et al., 1985; Sklar, 1988; Ling and Endlich, 1989; McKenna et al., 1990a, b; McKenna and Cotter, 1997) . In a second line of evidence, inhibition of RAS activation has resulted in radiosensitization both in rodent cells transfected with RAS (Bernhard et al., 1996) and in human tumor cell lines bearing endogenous mutations in RAS (Miller et al., 1993; Bernhard et al., 1998) . These studies have exploited independent methods to block RAS activation. Both lovastatin (Miller et al., 1993) and farnesyltransferase inhibitors (Bernhard et al., 1996) that block the processing of RAS result in radiosensitization. Similarly, transfection of cells expressing activated RAS with an adenoviral vector encoding a single-chain antibody fragment against RAS leads to radiosensitization through the inhibition of RAS action (Russell et al., 1999) . A similar result was seen with expression of an antisense vector to RAS (Rait et al., 2000) . Finally, we show below that tumor cells with endogenous RAS activation are more resistant to radiation than are their counterparts in which the mutant RAS oncogene has been eliminated by homologous recombination . Although there may be caveats about each of these lines of experimentation taken individually, together they offer a compelling case that expression of a mutant RAS allele can alter the sensitivity of tumor cells and cause increased survival after exposure to ionizing radiation. What remains unclear from these experiments is which downstream mediators of RAS result in altered radiosensitivity and whether there are upstream mediators that could produce a similar effect through wild-type RAS. Activation of RAS, either by mutation or through signaling from the cell-surface receptors, triggers a series of cascading activation of cytoplasmic kinases. The identification of the RAS signaling pathways that lead to altered radiation sensitivity thus becomes of considerable interest, because these pathways are potentially targets for manipulation of radiosensitivity in tumor cells. Additionally, because signaling cascades may converge from multiple upstream mediators, identification of the downstream elements involved with RAS may give insights into cases in which altered radiosensitivity is seen in the absence of a RAS mutation. It should be noted that although each of these target elements is present in normal cells, they are not aberrantly activated and thus are not likely to contribute to enhanced radiation survival as they do in transformed cells.
Of the RAS signaling pathways, the RAS-to-MAPK (mitogen-activated protein kinase) pathways are perhaps the most extensively studied, including the sequential kinase cascades RAS-RAF-MAPK (also known as extracellular regulated protein kinase) pathway, the stress-activated SAPK/JNK pathway, and the P38 pathway (Elion, 1998; Reuther and Der, 2000) . RAF has in fact been implicated in radiosensitivity. Kasid et al. (1987 Kasid et al. ( , 1993 transfected a truncated and therefore constitutively active RAFgene into a human squamous cell carcinoma cell line, leading to increased survival after radiation. The same group has also shown that downregulation of RAF through antisense oligonucleotide treatment increases the radiation sensitivity of human cells (Kasid et al., 1989) . In addition, Kasid et al. found that radiation itself induced RAF activation by colocalization of RAS and RAF to the inner cell membrane in cells with wild-type RAS (Kasid et al., 1996) , although the physiological consequence of that induction has not yet been explored. Hagan et al. (2000) showed that MEK inhibition made DU145 cells, cells with wild-type RAS, more radiosensitive and suggested that this was independent of apoptosis induction. In some cell lines with active RAS and wild-type P53, MEK inhibition might lead to radiosensitization through P53 induction. We have observed, however, that inhibition of MAPK by the MEK inhibitor PD98059 failed to radiosensitize cells with activated RAS , and Cox has produced similar data (Grana et al., 2002) that raises the possibility that another pathway may be involved.
RAS also signals by activating the catalytic p110 unit of phosphoinositide-3-kinase (PI3K) (Rodriguez-Viciana et al., 1994) . PI3K phosphorylates phosphatidylinositol (PtdIns) phosphates leading to the conversion of PtdIns 4,5-P2 to PtdIns 3,4,5-P3. This lipid second messenger aids in recruiting AKT (PKB) to the cell membrane through binding to its plextrin homology domain. In addition, it activates the phosphoinositidedependent kinases (PDK) PDK-1 and PDK-2, which then activate AKT through phosphorylation at two sites. The activation of PDKs and AKT is negatively regulated by the PTEN phosphatase that dephosphorylates PtdIns 3,4,5-P3 (Maehama and Dixon, 1998) . Mutation or loss of PTEN expression has been implicated in a number of cancers (Li et al., 1997; Shao et al., 1998; Soria et al., 2002) and in the Cowden disease hamartoma syndrome (Nelen et al., 1997) . AKT has been widely implicated as a cell survival factor under multiple conditions including exposure to cytotoxic agents and hormone manipulations (Coffer et al., 1998; Downward, 1998; Arase et al., 2000; Brognard et al., 2001; Gupta et al., 2002) . In addition to AKT, PI3K has other targets including P70S6 K, RAC, and guanine exchange factors (Carpenter and Cantley, 1996) . PI3K has been implicated in mitogenic signaling, inhibition of apoptosis, intracellular vesicle trafficking, and secretion and regulation of actin and integrin functions (Carpenter and Cantley, 1996; Krasilnikov et al., 1999; Gire et al., 2000) . RAS also activates RIN and RAL by direct binding. RAL can activate CDC42 and RAC, which activate the various MEK kinase proteins that are involved in the regulation of the SAPK/JNK and P38 pathway (Elion, 1998; Reuther and Der, 2000) .
Potential upstream mediators of altered radiosensitivity via RAS or other effectors are also an area of active investigation. Overexpression of the EGF receptor has been shown to accompany development and growth of malignant tumors, including those of the head and neck (H&N) (Shin et al., 1994) . There is increasing evidence that high-level expression of EGFR is associated with aggressive tumor growth and poor clinical outcome in these cancers (Grandis et al., 1998) . A number of studies have shown a positive relation between EGFR expression and tumor resistance to radiation (Sheridan et al., 1997) . Experimentally, Milas et al. (2000) demonstrated in mice with H&N carcinoma xenografts enhanced tumor radiosensitivity after combined treatment with C225 (monoclonal anti-EGFR antibody) and radiation. Bonner et al. (2000) have shown that combining C225 and radiation results in greater cell killing of squamous cell carcinoma lines than with either treatment alone. Harari and colleagues have also reported similar data both in vitro and in vivo (Bonner et al., 2000; Huang, 2001, 2002) . Signaling through the ERB family of receptors similarly led to altered radiosensitivity in a glioma cell line (O'Rourke et al., 1998) . The results of these studies have provided the basis for proceding with clinical trials (Robert et al., 2001) . The EGFR family consists of four closely related growth factor receptors, including EGFR or HER-1 (ERBB1), HER-2 (ERBB2/neu or P185 neu), HER-3 (ERBB3), and HER-4 (ERBB4). EGFR binds several distinct ligands, including EGF, transforming growth factor-a, and ampheregulins. Heregulins and neuregulins bind to ERBB3 and ERBB4. ERBB2 (HER-2/neu) does not directly bind to any known ligand. Instead, it forms heterodimers with the three other family members and, in so doing, enhances ligandbinding affinity and reduces the rate of ligand dissociation. HER-2/neu heterodimers also amplify growth factor signals through activation of the HER-2/neu intracellular kinase domain and autocross phosphorylation (reviewed in Klapper et al., 2000) . The detailed mechanism by which EGFR signaling leads to altered radiosensitivity is only partially defined. EGFR receptors initiate cytoplasmic signaling through autophosphorylation of their intracellular domains (Downward et al., 1984) . EGFR has a number of effectors that include RAS and PI3K. One of the areas that we discuss in this paper is the possibility that there might be common pathways mediating altered radiation sensitivity in tumors carrying different oncogenic mutations.
We have hypothesized that there is a signal transduction pathway that involves RAS, PI3K, and AKT and has a major influence on the survival of many different human tumor cell lines after exposure to ionizing radiation. We additionally hypothesize that this pathway can be activated either by mutational activation of RAS, or by overexpression or mutation of a receptor that signals through RAS or by loss of the PTEN tumor suppressor gene; therefore; this pathway potentially represents a common pathway affecting radiation survival for multiple different mutational events that occur in tumor cells. In this paper, we will review the data from our laboratory that has led us to these hypotheses.
Recent studies on RAS and radiation sensitivity
Multiple studies were published showing that transfection of an activated RAS allele into rodent cells resulted in cell lines that were more resistant to killing by ionizing radiation (FitzGerald et al., 1985; Sklar, 1988; Ling and Endlich, 1989; McKenna et al., 1990a, b) . A question that then remained to be answered was whether this had relevance to human malignancy. To address this question, we collaborated with Dr Eric Stanbridge to examine a series of cell lines derived from human carcinomas or sarcomas with naturally occurring RAS mutations from which cell lines had been derived to either knock out the mutant RAS allele by homologous recombination or had spontaneously lost the mutant RAS allele. In each case, we found that the cells that had lost the activated RAS had become more sensitive to killing by ionizing radiation (Figure 1 ). In one of these cell lines, a cell line derived from the HT1080 fibrosarcoma that carries one mutant N-RAS allele, we found that when we took the cell in which the mutated N-RAS allele had been spontaneously lost and now transfected in an activated N-RAS allele that we could restore the increased survival after radiation that had been previously seen. Therefore, we concluded that oncogenic RAS could alter the radiosensitivity of human tumors in a manner similar to the results seen in transfection systems.
A series of experiments was undertaken to distinguish among the downstream pathways that could be involved in this effect. We initially studied the RAS-RAF-MAPK pathway since it had been shown by Kasid and co-workers that a truncated and, therefore, activated RAF allele could also cause altered radiation sensitivity (see above and Kasid et al., 1987 Kasid et al., , 1993 . Two human bladder carcinoma cell lines, the T24 bladder squamous cell carcinoma cell line that is known to carry a mutated H-RAS allele, and RT4, a similar cell line in which the RAS allele is wild type, were chosen for analysis. Using the drug PD98059, which is known to inhibit MEK, we showed that this drug could not only inhibit the constitutively activated signaling through MEK seen in T24 but could also inhibit the radiationinduced activation of MAPK, which is seen in the RT4 cell line ( Figure 2 ); however; when we examined the effects of this drug on radiation survival, we found no effect (Figure 3) .
It should be noted that this experiment does not rule out an effect on radiation sensitivity involving RAF. It simply says that in this system, if RAF is having an effect, it is not acting through activation of MEK. Cox and colleagues have similarly shown in their system that MEK inhibition did not alter radiosensitivity but were also able to show that a constitutively active form of RAF would alter radiation sensitivity (Grana et al., 2002) . This led them to suggest that RAF contributes to Cells in log phase growth were plated and irradiated for clonogenic survival at the doses indicated. At 3 weeks after irradiation, plates were stained and scored for colony formation. SG-3 (J), DLD-1 cells expressing both activated and wild-type endogenous KRASalleles. SG-4 (') and SG-5 (m), DLD-1 cells expressing only the wild-type endogenous K-RAS allele. Bars, s.d.
altered radiosensitivity in an MEK independent manner, as yet undefined. We undertook a series of experiments to examine other potential pathways downstream of RAS including the PI3K pathway, the P70S6 kinase pathway, and the P38 pathway (Gupta et al., 2001a) . Again, initially this was approached by pharmacological inhibition (Figure 4) . Inhibition of the PI3K downstream target P70S6 K by rapamycin, the RAF-MEK-MAPK pathway with PD98059, or the RAS-MEK kinase-P38 pathway with SB203580 had no effect on radiation survival in cells with oncogenic RAS. The radiosensitization seen with inhibition of PI3K was of a similar order of magnitude to the radiosensitization that we had seen by inhibition of RAS itself and was not additive to the RAS effect. This was confirmed in a number of cell lines carrying activated RAS mutations.
To summarize, we found that only inhibition of PI3K ( Figure 5 ) led to radiosensitization. The PI3K inhibitor LY294002 radiosensitized cells bearing mutant RAS oncogenes, but the survival of cells with wild-type RAS and constitutively inactive PI3K was not affected (Gupta et al., , 2001a .
To demonstrate that it was in fact PI3K itself that was having this effect, we induced the active form of PI3K in cell lines that were not carrying RAS mutations to demonstrate that activation of the PI3K pathway, independent of activation of RAS, would lead to altered radiation survival. Since PI3K cannot, however, be constitutively expressed because it leads to permanent cell arrest, PI3K was placed downstream of a dexamethasone-inducible promoter and transfected into cells. In the absence of dexamethasone, PI3K was not expressed, and no phosphorylation was seen of AKT, which is downstream of PI3K. In the absence of expression, we saw no alteration in radiation sensitivity. When the cells were exposed to dexamethasone and active PI3K was expressed, as demonstrated by phosphorylation of AKT, we saw increased survival after exposure to ionizing radiation, and this increase in survival could in turn be inhibited by the pharmacologic inhibition of the induced PI3K (Figure 6) . Therefore, these experiments demonstrated not only that activation of PI3K was a marker for the pathway that is downstream of RAS in altering radiation survival, but also that PI3K is a part of this pathway. We concluded that RAS regulation of radiation sensitivity is correlated with activated PI3K, not with activation of MEK, P70S6 or P38, and that the phosphorylation of AKT is a marker for the resistant phenotype (Gupta et al., 2001a) . A series of preclinical animal experiments have been performed using a series of distinct farnesyltransferase inhibitors to block the activity of mutant RAS (CohenJonathan et al., 2000) . These were done in collaboration with Drs Sebti and Hamilton at the University of Pittsburgh and with Drs Gibbs and Kohl of Merck Research Laboratories. We found that these agents, as a class, could be used to alter the radiation sensitivity of fibroblasts transfected with mutant RAS alleles and of human tumor cell lines expressing naturally occurring H-RAS mutations. This work was taken into an animal model using the T24 bladder carcinoma cell line as a xenograft in nude mice. This cell line as noted above contains a mutant H-RAS allele. In both an in vivo to in vitro plating assay and in growth delay experiments, we could show that there was a synergistic interaction between the FTI and ionizing radiation (Figure 7 ) leading to increased radiation sensitivity of the tumor cells .
A multicenter phase I trial of the Merck L778,123 farnesyltransferase inhibitor plus radiotherapy in patients with H&N and lung carcinoma and patients with pancreatic carcinoma has been completed . Of significance, however, were the results seen in a group of non-small-cell lung patients in this trial. All of these patients had previously failed chemotherapy and had very bulky central mediastinal disease, and such Of the five patients who completed treatment on the trial, four had measurable disease and all had an objective response to treatment, three of them achieved complete response, and one achieved significant partial response; however, in none of the non-small-cell lung patients who responded to treatment did we find an activated RAS mutation. This finding has led to one of the most significant shifts in our thinking. At that time, we were focusing on RAS assuming that we were developing a strategy where agents might be used in the presence of an activated RAS mutation. The finding that we saw very significant responses in the absence of a RAS mutation led us to reconsider this hypothesis. There are obviously two possible explanations. One explanation is that RAS is not the target of the farnesyltransferase inhibitor, but rather the drug is acting through other farnesylated proteins as yet undefined. An alternative explanation is that RAS is the target of the drug but that activation of the pathway is not occurring by mutation but is occurring in some other way. It should be noted that these hypotheses are not mutually exclusive. We have begun to evaluate these possibilities experimentally. As noted above in our studies in the transfected cell lines in which we studied the effect of RAS on PI3K, we used the phosphorylation of AKT as a marker for the radioresistant phenotype in these cell lines since AKT is downstream of PI3K. We, therefore, undertook a study of a group of patients who had been treated in our clinic with squamous cell carcinoma of the H&N and who had received chemoradiation with carboplatin-paclitaxel induction followed by concurrent radiation . The question to be addressed was whether phosphorylation of AKT had any relationship to local outcome after combined modality treatment. A total of 51 patients had been entered into a phase II trial of this combination in our clinic and of these 51, 38 patients had sufficient material to study in terms of tissue blocks.
This study has also been published , but to briefly summarize the results, the samples were stained for EGFR expression, for pan-AKT expression and for the presence of phospho-AKT. Grading schemes for phospho-AKT and for EGFR expression were developed and were independently applied in a double-blinded manner by two pathologists for the extent of phospho-AKT and EGFR present in the samples. These were then correlated with local control. While there was a tendency for patients showing overexpression of EGFR to show increased local failure, this did not reach statistical significance in this study although perhaps with a larger group of patients it would have done so. Nevertheless, even in this small group of 38 patients there was a highly statistically significant correlation between the presence of phospho-AKT and local failure (Figure 8 ), suggesting that in these H&N patients there was also a strong correlation between activation of a signal transduction pathway involving AKT and altered radiation survival.
In published literature, PI3K has been shown to be activated by EGFR through RAS as well as in a RASindependent manner (Rodriguez-Viciana et al., 1994 , Chan et al., 2002 . A series of H&N carcinoma cell lines were studied to ask whether the activation of AKT was occurring by a pathway through RAS or independently of RAS since it is known that EGFR, for example, may activate PI3K directly or via interaction with RAS.
Figures 9 and 10 show the results with the squamous cell carcinoma cell line SQ20B. This is a cell line derived from a recurrent laryngeal carcinoma that has been in cell culture for many years and is known to be highly resistant to killing by ionizing radiation. This cell line not only overexpresses EGFR but also shows autophosphorylation of EFGR and the presence of phospho-AKT. When this cell line is treated with the drug Iressa, an inhibitor of EGFR kinase, loss of the autopho- Similarly, when the cell line was treated with the drug LY294002, a PI3K inhibitor, AKT phosphorylation was also lost , although neither of these drugs had any effect on the autophosphorylation of EGFR (Figure 9 ). This suggests two things. One, it suggests that indeed the activation of AKT is coming from a pathway where EGFR is signaling to PI3K through RAS. Also, since L744,832, the FTI used in this case, is only efficient at inhibiting the farnesylation of H-RAS and does not inhibit K-RAS prenylation, at the concentrations used in these experiments (Bernhard et al., 1996 , signaling to PI3K may primarily involve H-RAS since the FTI was as efficient at inhibiting AKT phosphorylation as the PI3K inhibitor. This is consistent with an emerging understanding of the role of the different species of RAS in receptor signaling where there are studies that now suggest that there may be preferential signaling to PI3K via H-RAS and to MAP kinase via K-RAS (Prior and Hancock, 2001; Prior et al., 2001; Zacharias et al., 2002; Jaumot et al., 2002; Van Meer, 2002) . When the effects of these drugs were studied on clonogenic survival, it could be seen that all three drugs -Iressa, L744,832 and LY294002 -could cause increased radiosensitivity (Figure 10 ) in the cell line SQ20B . Thus, our hypothesis is that the altered radiation sensitivity is occurring not only in situations where RAS is activated by mutation but also in situations where there is increased signaling through H-RAS by an upstream receptor. If this hypothesis proves to be correct, it may be possible to use FTIs that only act on H-RAS as radiation sensitizers in cells with autocrine growth factor signaling through RAS.
It is now possible to start to sketch a common pathway or pathways that affect the radiation sensitivity of solid tumors. Our own data suggest that signaling from EGFR via RAS to PI3K to AKT will lead to a phenotype type of altered sensitivity. Loss of the PTEN Figure 9 Inhibitors known to block EGFR signaling pathways. Signaling through EGFR was evaluated by immunoblot analysis using antibodies with activity against the active or phosphorylated forms of EGFR and AKT. H-RAS was used as a loading control. SQ20B cells were exposed to the indicated inhibitors The RAS signal transduction pathway WG McKenna et al oncogene, which acts as a negative regulator of PI3K signaling, may also be affecting radiation sensitivity by influencing signaling through this pathway. We have preliminary data to that effect and the laboratory of Dr M Pruschy (University of Zurich) also has similar data (personal communication). While we saw no effect in the cell lines that we have studied for an involvement of MEK, the group of Miura and colleagues (Tezuka et al., 2001) in Tokyo have data that suggest that from the IGF1 receptor crosstalk between RAS and RAF may be required to alter radiation survival. Certainly, the group of Kasid et al. (Kasid et al., 1987 Gokhale et al., 1999) has long demonstrated that RAF itself may be a target for altering radiation sensitivity in some situations, and similar conclusions have been drawn by Cox and colleagues (see Grana et al., 2002) . The downstream components of this pathway remain to be more fully elucidated. AKT has three isoforms and multiple potential downstream targets. These targets do not fall into easily generalizable categories, although several clearly do involve cell survival mechanisms. Testa and Bellacosa (2001) have pointed out that as a general mechanism phosphorylation events downstream of AKT frequently affect nuclear translocation of factors involved either in the regulation of cell cycle progression or of apoptosis. For example, AKT activates IKK resulting in NF-kB transcription of antiapoptotic genes (reviewed in Testa and Bellacosa, 2001; Thakkar et al., 2001; Cataldi et al., 2001; Chan et al., 2002; Edwards et al., 2002; Li and Zhu, 2002; Nicholson and Anderson, 2002) . In this regard, however, both Tofilon (Russell et al., 2002) and Cox (Grana et al., 2002) have produced data suggesting that NF-kB is not involved in the altered radiosensitivity seen with RAS. There are also alternative targets suggested by the work of others. There are data, for example, from Cohen-Jonathan and colleagues (see Ader et al., 2002; Delmas et al., 2002) that suggest that RhoB maybe a target for altering sensitivity. Sarkaria et al. (personal communication) have data that point to MTOR as a potential mediator of sensitivity, although in our experiments in vitro we saw no effect of the drug rapamycin (Gupta et al., 2001) . Nevertheless, a different situation may apply in vivo, and this certainly deserves further exploration.
Concluding remarks
In summary, we have made progress in outlining the components of a pathway that has a significant effect on the clonogenic survival of cells of human solid tumors after exposure to ionizing radiation. This pathway contains the elements EGFR, RAS, PI3K, and AKT (Gupta et al., 2001a (Gupta et al., , b, 2002 . Two clinical trials have addressed this hypothesis. One trial on the use of farnesyltransferase inhibitors with ionizing radiation demonstrated that drugs of this class could safely be given with radiation (Hahn et al., 2000a) . A second phase I trial of an orally administered FTI, as opposed to the intravenous agent used in our last trial, is already underway in our clinic. Additionally, we have data from a series of H&N cancer patients that strongly support our hypothesis that phosphorylation of AKT is a good marker for a resistant phenotype . We are now further exploring these data in lung and breast patients. We had initially hypothesized that the human tumor cells carrying oncogenic RAS mutations might best be targeted by agents that directly target RAS, and one could similarly argue on that reasoning that human tumor cells carrying activated or overexpressed EGFR might best be targeted with agents that directly target the EGFR, the EGF receptor. It is possible, however, that this reasoning is not correct and that one cannot a priori assume simply because one knows the mutational status of a tumor cell, that one therefore knows the best place to manipulate any given phenotype for a clinical purpose. The balance between efficacy and toxicity will determine the best approach in a clinical setting and this requires as complete a description of the desired effect at the molecular level as can be obtained. An additional consideration is that, while it is customary to depict signaling cascades as linear sequences, it is in fact known that these exist in a cell as components of an interactive branching network. This has important implications for therapeutic strategies. In a linear sequence, inhibition at any point should yield equivalent effects in terms of disrupting the downstream flow of signals. However, modern network theory holds that not all the nodes in a network are equivalent in terms of their effect, but that some nodes represent critical hubs for signal transduction and represent particularly vulnerable points for disruption of network activity (Barabasi 2002) . With the extensive crosstalk that we know exists in signal transduction pathways, it is necessary to determine the nodal or hub points at which networks may be most vulnerable to manipulation in clinical situations. It seems likely that many of the biologically targeted agents, that will become available to us in the next few years will have to be used in conjunction with conventional therapies in order to have their maximal effect. The story of Gleevec (Druker et al., 2002a, b; O'Dwyer et al., 2002 ) is an extremely heartening one for all who believe in molecularly targeted therapy. In this case, the targeted agent not only is highly selective for the tumor cells but also is able, by itself, to produce complete remissions and perhaps even cures. However, in this regard, Gleevec may turn out to be the exception rather than the rule. With many of the other biologically targeted agents that have been studied, although they may show significant responses, these responses are not different in magnitude to those that we see with conventional chemotherapeutic agents (Thomssen, 2001; Workman, 2001; Leyland-Jones, 2002; Pastan and Kreitman, 2002) . Therefore, it is likely that biological modifiers will have to be used in conjunction with other agents in order to produce their maximal effect. These other agents need to be selected carefully if this is to be done effectively. The recent highly disappointing results of Iressa in combination with conventional chemotherapy in lung cancer amply illustrate this (Henderson et al., 2002) . The ideal situation would be to combine these therapies in situations where not only do you get additive interactions between the biological agent and the conventional agent but where the two interact to produce a synergistic effect. Only by more completely defining the signal transduction pathways involved can one hope to go about doing this in a rational manner.
